| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Cash Flows (used in) from Operating Activities: | | | | | | | | |
| Net loss | -270.7 | -60.6 | -301.7 | -112.0 | -14.6 | -0.1 | 0.5 | -64.8 |
| Adjustments to reconcile net loss to net cash (used in) from operating activities: | | | | | | | | |
| Depreciation and amortization expense | 27.3 | 27.2 | 26.4 | 25.3 | 19.8 | 19.0 | 18.7 | 17.0 |
| Change in fair value of contingent consideration | -11.8 | -4.1 | 4.5 | 0.9 | -5.8 | -4.7 | -7.5 | -3.9 |
| Change in fair value of warrant liabilities | 1.7 | -2.0 | -81.2 | 65.7 | -30.2 | -27.2 | -58.3 | 14.7 |
| Loss on extinguishment of debt | | | | | | 1.4 | -0.1 | |
| Fixed asset abandonment | 1.7 | | | | | | | |
| Amortization of debt issuance costs | 1.4 | 1.1 | 1.1 | 1.2 | 0.8 | 0.7 | 0.7 | -4.4 |
| Non-cash lease expense | 0.8 | 0.8 | -1.8 | 4.7 | 1.9 | 1.7 | | |
| Stock-based compensation, net | 2.0 | 9.4 | 12.1 | 11.0 | 17.8 | 13.8 | 14.9 | 9.5 |
| Paid in kind interest expense | 5.3 | 2.1 | | | | | | |
| Credit loss on other assets | 62.0 | | | | | | | |
| Changes in operating assets and liabilities: | | | | | | | | |
| Accounts receivable, net | 135.1 | -8.4 | -30.8 | -8.4 | -9.3 | -58.3 | 10.4 | -19.1 |
| Other assets | -0.5 | -0.1 | -0.8 | 3.7 | 10.2 | -3.1 | -6.7 | -3.9 |
| Prepaid expenses and other current assets | 4.3 | -3.7 | -4.2 | -29.7 | -19.6 | 1.8 | 10.8 | -6.3 |
| Interest accrued due to sellers | | | | | 0.0 | 0.1 | 0.3 | 0.3 |
| Accounts payable and accrued expenses | 16.7 | 11.5 | 1.7 | 40.3 | -19.4 | 10.0 | -6.9 | 26.2 |
| Other liabilities | 9.2 | -2.7 | -11.1 | -7.1 | 3.2 | 7.4 | -0.8 | -1.5 |
| Net cash (used in) provided by operating activities | -15.5 | -29.5 | -62.2 | -2.0 | -45.0 | -37.2 | -23.5 | -36.4 |
| |
| Cash Flows (used in) from Investing Activities: | | | | | | | | |
| Purchase of property and equipment | -6.2 | -5.1 | -10.5 | -18.6 | -12.7 | -7.8 | -11.1 | -15.5 |
| Acquisitions of subsidiaries including non-compete intangibles, net of cash acquired | | | -0.8 | | -1.5 | -3.5 | -4.8 | -451.1 |
| Payments to sellers | -2.1 | -4.4 | -4.7 | -0.3 | -1.7 | -2.2 | -2.4 | -0.2 |
| Net cash (used in) provided by investing activities | -8.2 | -9.5 | -16.0 | -18.9 | -15.8 | -13.5 | -18.4 | -466.8 |
| |
| Cash Flows (used in) from Financing Activities: | | | | | | | | |
| Payments of long-term debt | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -1.6 | -253.7 |
| Debt issuance costs | 0.0 | -9.2 | | | 0.0 | -0.1 | -0.9 | -5.2 |
| Proceeds from long-term debt | | 150.0 | | | | | | 825.0 |
| Proceeds from CS Revolving Line of Credit | 40.0 | 15.0 | 84.0 | 25.0 | | | | -175.0 |
| Repayments of CS Revolving Line of Credit | -30.0 | -99.0 | | -25.0 | | | | 2.4 |
| Proceeds from insurance financing arrangements | | 2.7 | | | | 2.5 | 0.0 | |
| Payments of principal on insurance financing arrangements | -0.7 | -0.7 | -0.5 | -0.7 | -0.7 | -0.7 | -0.3 | -0.4 |
| Other | -1.0 | -0.6 | | | -2.1 | 0.4 | | 0.1 |
| Net cash (used in) provided by financing activities | 6.6 | 56.5 | 81.4 | -2.9 | -4.4 | 0.5 | -3.8 | 392.8 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -17.2 | 17.6 | 3.2 | -23.8 | -65.2 | -50.1 | -45.7 | -110.4 |
| |
| Cash, cash equivalents and restricted cash at beginning of year | | | | | | | | |
| Cash, cash equivalents and restricted cash at end of period | | | | | | | | |
| Supplemental cash flow information: | | | | | | | | |
| Interest paid | 15.3 | 25.2 | 23.0 | 10.6 | 23.1 | 4.5 | 13.8 | 16.2 |
| Income taxes paid | | | 0.5 | | 0.1 | 0.0 | | 1.2 |
| Non-cash investing and financing activities: | | | | | | | | |
| Right-of-use assets obtained in exchange of lease liabilities | 5.1 | 11.5 | 13.3 | 8.3 | 23.9 | 26.4 | | |
| Issuance of Class A common stock for acquisitions | 0.1 | 14.3 | -15.6 | 39.1 | | 15.8 | 3.0 | 1.5 |
| Due to sellers in connection with acquisitions | | | | -3.5 | 3.4 | 0.1 | | -0.3 |
| Addition to construction in process funded through accounts payable | 0.0 | 0.9 | | -3.6 | 0.6 | 3.0 | | |
| Humana Affiliate Provider clinic leasehold improvements | -0.1 | 0.4 | | -2.9 | 0.8 | 2.2 | | -2.9 |
| Employee Stock Purchase Plan issuance | | 1.1 | | | | 9.7 | | |
| Warrants issued | | 45.7 | | | | | | |